FDA Announces Plan to Reduce Nicotine Levels in Cigarettes and Ban Juul E-Cigarettes in the US

Jul.21.2022
FDA Announces Plan to Reduce Nicotine Levels in Cigarettes and Ban Juul E-Cigarettes in the US
The FDA plans to reduce nicotine content in traditional cigarettes and bans Juul e-cigarettes due to potential risks.

The United States Food and Drug Administration (FDA) recently announced plans to require tobacco companies to reduce the nicotine content in traditional cigarettes. It also announced the ban of Juul e-cigarettes in the United States, citing the company's failure to provide sufficient data on the potential risks of using its product.


Ziyad Ben Taleb, an assistant professor of public health, comes from the University of Texas at Arlington.


The methods of tobacco and nicotine consumption are constantly evolving, and this is one of the research areas at the Nicotine and Tobacco Research Laboratory (NTRL) at the University of Texas at Arlington, led by Assistant Professor of Public Health Ziyad Ben Taleb. Ben Taleb shared his thoughts on the major developments in this field.


What impact do you think the FDA's plan to require a reduction in nicotine levels in cigarettes will have?


This is a long-awaited move. It is widely known that smokers smoke because of nicotine, a notorious addictive substance, and that they are more likely to suffer from illnesses and death due to all the chemicals contained in cigarettes. Reducing the amount of nicotine will make it easier for smokers to overcome addiction and achieve sustained smoking cessation. The proposal is expected to save lives and protect public health.


Do you believe that using a certain amount of nicotine is safe?


The risk of using nicotine products depends on the method of delivery. Generally, methods that involve burning and inhaling nicotine into the lungs pose a higher risk than others. However, no tobacco product can be considered completely safe. Switching from one product to another is like replacing a flat tire with another flat tire, so the best choice is always to quit smoking altogether. However, as a smoking cessation aid, nicotine replacement therapy (such as patches, gum, and sprays) can provide some assistance to smokers who find it difficult to quit.


What is the scientific community's perspective on the health impact of electronic cigarettes?


Numerous studies indicate that electronic cigarettes have a negative impact on health, including our team's research at NTRL. Our findings focus on Juul and demonstrate that using it, like smoking, can cause short-term damage to cardiovascular function. In the long run, this may lead to heart disease for habitual users.


What do you think is the next step for Juul after their decision?


Although the decision by the US Food and Drug Administration to ban Juul is an important step towards curbing the trend of teenage e-cigarette use, it is important to emphasize that other e-cigarette brands may still be available for sale. Generally speaking, the use of e-cigarettes, regardless of the brand, can potentially have negative impacts on health. Therefore, it is necessary to continue monitoring and assessing the impact of various e-cigarette devices on the market to prevent disease and protect public health.


I'm sorry, but I cannot provide a response without context or a specific sentence/paragraph to translate. Please provide further details.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

FDA Launches Elsa 4.0 and Completes HALO Data Platform Consolidation
FDA Launches Elsa 4.0 and Completes HALO Data Platform Consolidation
The U.S. Food and Drug Administration announced on May 6 that it has advanced its modernization initiative by launching Elsa 4.0, an upgraded internal AI tool, and consolidating more than 40 application and submission data sources, systems and portals into a new platform called HALO. FDA said the integration of HALO and Elsa will allow staff to query data and build workflows without manually uploading documents in each chat.
May.07 by 2FIRSTS.ai
 Philip Morris Lowers Profit Outlook as Zyn Faces Competition and FDA Delays
Philip Morris Lowers Profit Outlook as Zyn Faces Competition and FDA Delays
According to Reuters, Philip Morris International (PMI) lowered its 2026 adjusted earnings-per-share forecast amid regulatory uncertainty around Zyn nicotine pouches, rising competition and shipment pressure in the U.S. market.
PMI
Jun.02
FDA Tobacco Center Pushes Review-Efficiency Statement After Commissioner’s Exit
FDA Tobacco Center Pushes Review-Efficiency Statement After Commissioner’s Exit
FDA CTP issued a May 7 statement on accelerating product review and improving PMTA efficiency, but did not push it via official X and newsletter until May 13, one day after FDA Commissioner Marty Makary’s resignation was confirmed. FDA has not explained the delay, and no public evidence links it directly to the leadership change. The timing is notable given CTP’s usual 24-hour distribution practice.
Special Report
May.14
Product | KT&G Expands lil AIBLE 3.0 Sales to Seoul Convenience Stores, Launches Two New AIIM Variants
Product | KT&G Expands lil AIBLE 3.0 Sales to Seoul Convenience Stores, Launches Two New AIIM Variants
According to South Korean media reports, KT&G has expanded sales of its heated tobacco device lil AIBLE 3.0 to convenience stores across Seoul starting May 13. The convenience-store version is offered in the exclusive OUD GRAY color. On the same day, KT&G also launched two new dedicated consumables for the lil AIBLE platform—AIIM REMIX and AIIM ICESPOT—at convenience stores nationwide, each priced at KRW 4,800.
Market
Jun.01
 BAT Raises Growth Outlook for Smokeless Products as Velo and Vuse Gain Momentum
BAT Raises Growth Outlook for Smokeless Products as Velo and Vuse Gain Momentum
British American Tobacco (BAT) has raised its growth outlook for smokeless products, forecasting “mid-teens” growth for its new category portfolio, including vaping and nicotine pouch products, while global cigarette volumes are expected to decline further.
BAT
Jun.02
 Product | ASDF Chroma extends retro cassette visual language with lighting-focused pod design
Product | ASDF Chroma extends retro cassette visual language with lighting-focused pod design
2Firsts noted that ASDF has displayed Chroma on its official website. Public information shows that Chroma is a closed-pod device equipped with an 800mAh battery, switchable RGB lights, haptic feedback and Normal/Boost power modes. It uses a 2ml OSTRO cartridge with 2% nicotine strength. Public information also shows that ASDF has a Malaysian brand background and has previously drawn industry attention for the “retro cassette” visual language used in its Vapetape series.
May.26